Unlocking Genomic Insights

Discover the power of comprehensive genetic testing. At Nextgenkaryo, we're dedicated to providing leading-edge cytogenomic services. Learn how our expertise can support oncologists, hospitals, researchers, and pharmaceutical partners in diagnostics, prognostics, discovery, and product development.

Cytogenomic Assays

We offer a comprehensive suite of Cytogenomic tests, tailored to meet the diverse needs of our clients. Our services are designed to support diagnostic, prognostic, disease monitoring, cellular integrity in oncology, research, and pharmaceutical development.

Karyology (Study of chromosomes)

The CLIA validated assay is performed on bone marrow, peripheral blood, lymph node, disaggregated tissue.

The disease type are Chronic Myeloid Leukemia (CML), Myelodysplastic Syndrome(MDS), Acute Myeloid Leukemia (AML), Myeloproliferative Neoplasms (MPN), Multiple Myeloma(MM), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Solid Lymphocytic Lymphoma (SLL), Lymphoma 

Solid tumor and hES cells karyotyping

The CLIA validated Karyotyping is performed on short term cultures grown as Short Term Cultures

Fluorescent in situ hybridization - Solid tumor

FISH is performed on Formalin fixed paraffin embedded (FFPE) tissue

Lung Cancer panel

FDA approved ALK BA

ROS1

RET

MET

Breast Cancer

Pathvysion- FDA approved Her2 neu FISH

Exploratory Services using culturing and karyology

New Cell line characterization

DNA damage and repair studies using chromosomal breaks and gaps, micronucleus

Culture expansion and maintaining cell line cultures for fresh cells for downstream exploratory testing.

Exploratory Services uisng FISH for Genetic marker testing

Bladder cancer

Oligodendrogliomas

Cholangiocarcinoma

premalignant lesions of Cervical cancers

Mutagen and Clastogen identification studies.

Fluorescent in Situ Hybridization - Heme malignancies

The CLIA validated Fluorescent in situ hybridization is performed on Bone marrow, peripheral blood, Lymph node and disaggregrated tissue.

Myelodysplastic Syndrome/Acute Myeloid Leukemia

5p12/EGR1

CEP7/7q31

CEP8

D20S108

MLL

BCL6

CEP8/MYC/IGH

IGH/BCL2

ETO/AML1

Chronic Lymphocytic Leukemia/Solid Lymphocytic Lymphoma

IGH/CCND1

ATM/TP53

CEP12/D13S319/13q34

CEP6/MYB)

Multiple Myeloma (CD138 enriched cells)

IGH/CCND1

IGH/MAF

IGH/MAFB

CDKN2C/CDKN2A

5p12/CEP9/CEP15

17p13

Myeloproliferative Neoplasms

FIP1L1/CHIC2/PDGFRA

PDGFRB

Transplant Monitoring

XY FISH

Chronic Myeloid Leukemia

BCR/ABL/ASS1

17p13

CEP8

Non Hodgkins Lymphoma

CCND1/IGH

BCL6 (3q27)

CEP8/MYC/IGH

IGH/BCL2

Acute Lymphocytic Leukemia

TCF3/PBX1

Cen 4/Cen 10/Cen 17

BCR/ABL1/ASS1

MLL

IGH

MYC

Quality Control Assay

Cell line integrity before biobanking or after retrieval from biobanking

Biologics and Therapeutics

Safety and Efficacy studies

Culture expansion

Stress studies on cells

Genomic instability

Genetic consistency before biobanking and after retrieval from biobanking

Data Management services

Data Transfer

Data Extraction and Transformations

Data Analytics

We serve

We serve Oncologists, hospitals, CROs, pharmaceutical partners and researchers for diagnostic/ prognostic testing, discovery and product development.